

DT13 Rec'd PCT/STO 16 FEB 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Hans-Juergen Krause et al.
PCT Application No.	PCT/IB2003/004502
PCT Filing Date:	15 August 2003
U.S. Serial No.:	(not yet assigned)
Filed:	(concurrently herewith)
Priority Date:	16 August 2002
Entitled:	FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF- α ASSOCIATED DISORDERS

ART UNIT: (not yet assigned)

EXAMINER: (not yet assigned)

Attorney Docket No.: BBC-166

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. EU509624024US, in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

February 16, 2005
Date


Lisa Rasmussen

**Transmittal of Sequence Listing, Computer Readable Form, and Amendment Pertaining
Thereeto For Invention Containing Nucleotide and/or Amino Acid Sequence
Under 37 CFR §§1.821-1.825**

Sir:


Transmitted herewith please find: a diskette containing a computer readable form (CRF) copy of the Sequence Listing, and a paper copy of the Sequence Listing for the patent application filed currently herewith this paper.

Applicants have assigned a separate identifier to each of the 34 sequences disclosed, as required by 37 CFR §§1.821-1.825.

Applicants verify the following:

1. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are the same in content, as required by 37 CFR §1.821(f);
2. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application contain no new matter and do not go beyond the original disclosure of the application, as required by 37 CFR §1.821(g);
3. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are in a form and format in accordance with 37 CFR §§1.822, 1.823, and 1.824.

Respectfully submitted,



John D. Conway
Registration No. 39,150
Attorney for Applicants
Abbott Bioresearch Center
telephone: (508) 688-8046
telefax: (508) 688-8110